The efficacy and safety of venetoclax combined with reduced dose HAD regimen in the treatment of newly diagnosed acute myeloid leukemia (AML) was investigated. From May 2022 to January 2023, a total of 25 patients with newly diagnosed AML were treated with venetoclax combined with reduced-dose HAD regimen as induction therapy. Accoding to the 2017 ELN recommendations, 13 (52.0%) in favoable, 3 (12.0%) in intemediate, and 9 (36.0%) in adverse. The ORR (CR rate+PR rate) was 88.0%, and the CR rate was 84.0%. By May 30, 2023, with a median follow-up of 9 months, 1 year overall survival, event-free survival, and relapse-free survival were 100%, 94.7%, and 94.7%, respectively. All patients received 1-5 cycles of consolidation therapy and two median cycles. Treatment with venetoclax and reduced dose of HAD regimen in the treatment of patients with newly diagnosed AML was high effective and safe.
通过回顾性分析自2022年5月至2023年1月收治的25例初诊急性髓系白血病（AML）患者，探索应用维奈克拉联合减低剂量HAD（高三尖杉酯碱+柔红霉素+阿糖胞苷）方案诱导治疗初诊AML的疗效及安全性。按照ELN 2017预后分层标准，低危组13例（52.0%），中危组3例（12.0%），高危组9例（36.0%）。1个疗程诱导治疗总体有效率（完全缓解率+部分缓解率）88.0%，1个疗程完全缓解率84.0%。截至2023年5月30日，中位随访9个月，全部患者诱导治疗后给予巩固治疗2（1~5）个周期。1年总生存率、无事件生存率、无复发生存率分别为100%、94.7%、94.7%。维奈克拉联合减低剂量HAD诱导方案，1个疗程完全缓解率高，安全性良好。.